RxDoctor Payments Data

Teresa King, MD

Gastroenterology · Lawrence, KSNPI 1982601381

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.3% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 32.9% of the total. 2025 is the largest year on record at $812, more than ten times the $11 reported in 2019. That places this record below the midpoint for gastroenterology clinicians in KS, where the typical reported total is $1,362.

$1,095in general payments, 2019–2025

Across 43 payments — averaging $25.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$360
  • Johnson & Johnson$241
  • Takeda Pharmaceuticals U.S.A., Inc.$225
  • Regeneron Healthcare Solutions, Inc.$102
  • Pfizer$41
  • Sanofi$39
  • plus $87 from 4 others

What the payments were for

  • Food & beverage$98990%
  • Education$10610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,095 in reported general payments places this provider in the 45th percentile of 98 gastroenterology providers in Kansas.

See all gastroenterology providers in Kansas

Medicare billing

Part B allowed, 2024
$116,463
Medicare patients
644
Services billed
872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab14$144,047
Mesalamine40$15,975
TrulancePlecanatide11$6,038
Dexlansoprazole DrDexlansoprazole13$1,910
Omeprazole263$1,825
Pantoprazole Sodium43$940
Sulfasalazine DrSulfasalazine11$851
Sucralfate20$829
Sulfasalazine12$580
Famotidine88$569
Colestipol Hcl14$492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$24$6,03811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 98 gastroenterology providers in Kansas.

Other gastroenterology in Lawrence

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →